⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL136646 | 1.00 | — | — | |
| SCHEMBL12341578 | 1.00 | — | — | |
| Homoserine Lactone SCHEMBL319044 | 0.92 | — | — | |
| SCHEMBL3988875 | 0.91 | — | — | |
| SCHEMBL1080050 | 0.90 | — | — | |
| SCHEMBL3149044 | 0.90 | — | — | |
| SCHEMBL12341644 | 0.90 | — | — | |
| Ethyl Acetate SCHEMBL7162873 | 0.90 | — | — | |
| SCHEMBL12341575 | 0.89 | — | — | |
| SCHEMBL131906 | 0.89 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 372 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4702981-A1 | TARGETED ANTIBACTERIAL TREATMENT | Københavns Universitet (DK) | 2026-03-04 | — | — | EP | claimed |
| US-20260035729-A1 | CREATING A VIBRIO-BASED EDUCATIONAL TOOLSET FOR PROTEIN SIGNALING | BIO RAD LABORATORIES INC (US) | 2026-02-05 | — | — | US | claimed |
| CN-119612759-A | Method for relieving anaerobic digestion ammonia nitrogen inhibition by using signal molecules and biochar and application thereof | 江南大学 | 2025-03-14 | — | — | CN | claimed |
| CN-114057284-B | Device and method for improving salt impact resistance of anaerobic ammonia oxidation particle system based on quorum sensing | 北京工业大学 | 2024-04-19 | — | — | CN | claimed |
| US-11944676-B2 | Systems and methods for the control of acute hepatopancreatic necrosis disease | PEBBLE LABS INC. (US) | 2024-04-02 | — | — | US | claimed |
| CN-117431183-A | Salt-tolerant heterotrophic nitrification-aerobic denitrification strain for producing acyl homoserine lactone and application thereof | 太原理工大学 | 2024-01-23 | — | — | CN | claimed |
| CN-116239711-B | Method for removing SBS homogeneous hydrogenation catalyst in SEBS solution | 华东理工大学 | 2023-09-12 | — | — | CN | claimed |
| CN-116239711-A | Method for removing SBS homogeneous hydrogenation catalyst in SEBS solution | 华东理工大学 | 2023-06-09 | — | — | CN | claimed |
| CN-113122553-B | N-acyl homoserine lactone acyltransferase encoding gene aigA and application thereof | 华南农业大学 | 2023-03-31 | — | — | CN | claimed |
| CN-113106111-B | N-acyl homoserine lactone acyltransferase encoding gene aigC and application thereof | 华南农业大学 | 2023-03-31 | — | — | CN | claimed |
| US-20230038480-A1 | SYSTEM FOR PRODUCITON OF HIGH YIELD OF RECOMBINANT PROTEINS | UNIVERSITY OF MARYLAND, COLLEGE PARK (US) | 2023-02-09 | — | — | US | claimed |
| US-20220304313-A1 | METHODS FOR DEGRADING AHL SIGNALING MOLECULES OR PREVENTING PLANT DISEASE CAUSED THEREBY | SOUTH CHINA AGRICULTURAL UNIVERSITY (CN) | 2022-09-29 | — | — | US | claimed |
| CN-112986420-B | Method for detecting microbial aggregate quorum sensing effect molecules by UPLC-MS/MS method | 军事科学院军事医学研究院环境医学与作业医学研究所 | 2022-09-13 | — | — | CN | claimed |
| CN-113322269-B | Biosensor based on bacterial population density sensing protein LuxR and application thereof | 中国人民解放军军事科学院军事医学研究院 | 2022-08-09 | — | — | CN | claimed |
| CN-114057284-A | Device and method for improving salt impact resistance of anaerobic ammonia oxidation particle system based on quorum sensing effect | 北京工业大学 | 2022-02-18 | — | — | CN | claimed |
| EP-0994961-B1 | HOMOSERINE LACTONES BIOFILM REGULATING COMPOUNDS AND THEIR METHODS OF USE | UNIV MONTANA STATE (US) | 2006-10-18 | — | — | EP | claimed |
| EP-0994961-A4 | HOMOSERINE LACTONES BIOFILM REGULATING COMPOUNDS AND THEIR METHODS OF USE | UNIV MONTANA RES DEV INST (US) | 2003-01-15 | — | — | EP | claimed |
| EP-0994961-A2 | HOMOSERINE LACTONES BIOFILM REGULATING COMPOUNDS AND THEIR METHODS OF USE | The Research and development Institute, Inc (US) | 2000-04-26 | — | — | EP | claimed |
| WO-1998058075-A2 | HOMOSERINE LACTONES BIOFILM REGULATING COMPOUNDS AND THEIR METHODS OF USE | THE RESEARCH AND DEVELOPMENT INSTITUTE, INC. (US) | 1998-12-23 | — | — | WO | claimed |
| US-12595468-B2 | Transcriptional recording by CRISPR spacer acquisition from RNA | ETH Zürich (CH) | 2026-04-07 | — | — | US | disclosed |
| US-12571789-B1 | Microbial subsurface soil sensors | RTX BBN TECHNOLOGIES, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| EP-4702981-A1 | TARGETED ANTIBACTERIAL TREATMENT | Københavns Universitet (DK) | 2026-03-04 | — | — | EP | disclosed |
| US-12565474-B2 | Discovery, total synthesis, and bioactivity of doscadenamides | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2026-03-03 | — | — | US | disclosed |
| US-20260035729-A1 | CREATING A VIBRIO-BASED EDUCATIONAL TOOLSET FOR PROTEIN SIGNALING | BIO RAD LABORATORIES INC (US) | 2026-02-05 | — | — | US | disclosed |
| EP-3833366-B1 | MICROORGANISM MIXTURES, MOLECULES DERIVED THEREFROM, AND METHODS OF USE THEREOF | B G NEGEV TECHNOLOGIES AND APPLICATIONS LTD AT BEN GURION UNIV (IL) | 2025-12-03 | — | — | EP | disclosed |
| US-20250352625-A1 | METHODS AND COMPOSITIONS FOR METHIONINE RESTRICTION | PETRI BIO, INC. (US) | 2025-11-20 | — | — | US | disclosed |
| EP-4584280-A1 | MATERIALS AND METHODS TO PRODUCE INSECTICIDAL TOXINS | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2025-07-16 | — | — | EP | disclosed |
| US-20250223544-A1 | SYNTHETIC QUORUM-REGULATED LYSIS | UNIV CALIFORNIA (US) | 2025-07-10 | — | — | US | disclosed |
| EP-2925139-B1 | FERMENTED SOIL ADDITIVE | LIQUID FERTILISER SYSTEMS PTY LTD (AU) | 2025-04-30 | — | — | EP | disclosed |
| CN-119804714-A | LC-MSMS-based method for quantifying anaerobic fermentation substances and AHLs in activated sludge | 农业农村部成都沼气科学研究所 | 2025-04-11 | — | — | CN | disclosed |
| EP-4531881-A2 | METHODS AND COMPOSITIONS FOR METHIONINE RESTRICTION | Petri Bio, Inc. (US) | 2025-04-09 | — | — | EP | disclosed |
| CN-119612759-A | Method for relieving anaerobic digestion ammonia nitrogen inhibition by using signal molecules and biochar and application thereof | 江南大学 | 2025-03-14 | — | — | CN | disclosed |
| CN-119612759-A | Method for relieving anaerobic digestion ammonia nitrogen inhibition by using signal molecules and biochar and application thereof | 江南大学 | 2025-03-14 | — | — | CN | disclosed |
| US-20250058002-A1 | ELECTROCHEMICAL INHIBITION OF REDOX ACTIVE BACTERIA AND RELATED DEVICES, METHODS AND SYSTEMS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE NAVY | 2025-02-20 | — | — | US | disclosed |
| US-12209256-B2 | System for protein inactivation and recombinant phages for targeted bacterial killing, infection, biodetection, and as a means of protein extraction | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2025-01-28 | — | — | US | disclosed |
| US-12191002-B2 | Dynamic characterization of synthetic genetic circuits in living cells | MICROSOFT TECHNOLOGY LICENSING, LLC (US) | 2025-01-07 | — | — | US | disclosed |
| CN-119157148-A | Application of quorum sensing quenching enzyme in pathogenic control of vibrio coralloides | 华侨大学 | 2024-12-20 | — | — | CN | disclosed |
| EP-3815088-B1 | DYNAMIC CHARACTERIZATION OF SYNTHETIC GENETIC CIRCUITS IN LIVING CELLS | MICROSOFT TECHNOLOGY LICENSING LLC (US) | 2024-07-24 | — | — | EP | disclosed |
| CN-118240913-A | Quorum sensing quenching enzyme and screening method and application thereof | 深圳先进技术研究院 | 2024-06-25 | — | — | CN | disclosed |
| CN-112703249-B | Transcription recording by CRISPR spacer sequences obtained from RNA | 苏黎世联邦理工学院 | 2024-05-17 | — | — | CN | disclosed |
| CN-117925676-A | Modularized orthogonal eukaryotic transcription factor model construction method | 中国科学院深圳先进技术研究院 | 2024-04-26 | — | — | CN | disclosed |
| CN-114057284-B | Device and method for improving salt impact resistance of anaerobic ammonia oxidation particle system based on quorum sensing | 北京工业大学 | 2024-04-19 | — | — | CN | disclosed |
| CN-114057284-B | Device and method for improving salt impact resistance of anaerobic ammonia oxidation particle system based on quorum sensing | 北京工业大学 | 2024-04-19 | — | — | CN | disclosed |
| US-11944676-B2 | Systems and methods for the control of acute hepatopancreatic necrosis disease | PEBBLE LABS INC. (US) | 2024-04-02 | — | — | US | disclosed |
| WO-2024052546-A1 | MATERIALS AND METHODS TO PRODUCE INSECTICIDAL TOXINS | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2024-03-14 | — | — | WO | disclosed |
| EP-4335866-A1 | MATERIALS AND METHODS TO PRODUCE INSECTICIDAL TOXINS | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2024-03-13 | — | — | EP | disclosed |
| CN-117431183-A | Salt-tolerant heterotrophic nitrification-aerobic denitrification strain for producing acyl homoserine lactone and application thereof | 太原理工大学 | 2024-01-23 | — | — | CN | disclosed |
| WO-2023235846-A2 | METHODS AND COMPOSITIONS FOR METHIONINE RESTRICTION | PETRI BIO, INC. (US) | 2023-12-07 | — | — | WO | disclosed |
| CN-112694170-B | Method and device for improving anaerobic ammonia oxidation denitrification effect and operation stability at low temperature | 北京工业大学 | 2023-11-17 | — | — | CN | disclosed |
| CN-116239711-B | Method for removing SBS homogeneous hydrogenation catalyst in SEBS solution | 华东理工大学 | 2023-09-12 | — | — | CN | disclosed |
| US-20230282303-A1 | DYNAMIC CHARACTERIZATION OF SYNTHETIC GENETIC CIRCUITS IN LIVING CELLS | MICROSOFT TECHNOLOGY LICENSING, LLC | 2023-09-07 | — | — | US | disclosed |
| US-20230242482-A9 | DISCOVERY, TOTAL SYNTHESIS, AND BIOACTIVITY OF DOSCADENAMIDES | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2023-08-03 | — | — | US | disclosed |
| US-20230240305-A1 | STABILIZED MUTANTS OF QUORUM QUENCHING LACTONASE AND USE THEREOF IN TREATMENT OF PATHOGENS | MIGAL GALILEE RESEARCH INSTITUTE LTD. (IL) | 2023-08-03 | — | — | US | disclosed |
| US-20230225332-A1 | COMPOSITIONS COMPRISING AROMATIC DIPEPTIDES-BASED STRUCTURES ENCAPSULATING AN ESTERASE AND USES THEREOF | MIGAL GALILEE RES INSTITUTE LTD (IL) | 2023-07-20 | — | — | US | disclosed |
| US-11694766-B2 | Dynamic characterization of synthetic genetic circuits in living cells | MICROSOFT TECHNOLOGY LICENSING, LLC (US) | 2023-07-04 | — | — | US | disclosed |
| CN-116239711-A | Method for removing SBS homogeneous hydrogenation catalyst in SEBS solution | 华东理工大学 | 2023-06-09 | — | — | CN | disclosed |
| CN-114634891-B | Bacillus bailii ZH3 and application thereof | 厦门萤星海科技有限公司 | 2023-06-02 | — | — | CN | disclosed |
| EP-4167745-A1 | COMPOSITIONS COMPRISING AROMATIC DIPEPTIDES-BASED STRUCTURES ENCAPSULATING AN ESTERASE AND USES THEREOF | Migal Galilee Research Institute Ltd. (IL) | 2023-04-26 | — | — | EP | disclosed |
| CN-112961847-B | Application of Bacillus belgii YtnP-homologous lactonase in oral cavity department hygiene disinfection | 华侨大学 | 2023-03-31 | — | — | CN | disclosed |
| CN-113122553-B | N-acyl homoserine lactone acyltransferase encoding gene aigA and application thereof | 华南农业大学 | 2023-03-31 | — | — | CN | disclosed |
| CN-113106111-B | N-acyl homoserine lactone acyltransferase encoding gene aigC and application thereof | 华南农业大学 | 2023-03-31 | — | — | CN | disclosed |
| US-20230038480-A1 | SYSTEM FOR PRODUCITON OF HIGH YIELD OF RECOMBINANT PROTEINS | UNIVERSITY OF MARYLAND, COLLEGE PARK (US) | 2023-02-09 | — | — | US | disclosed |
| US-20230038480-A1 | SYSTEM FOR PRODUCITON OF HIGH YIELD OF RECOMBINANT PROTEINS | UNIVERSITY OF MARYLAND, COLLEGE PARK (US) | 2023-02-09 | — | — | US | disclosed |
| US-20220411390-A1 | MODULATION OF BACTERIAL QUORUM SENSING WITH SYNTHETIC LIGANDS | WISCONSIN ALUMNI RES FOUND (US) | 2022-12-29 | — | — | US | disclosed |
| US-20220403419-A1 | CRISPR-BASED METHODS FOR RECORDING BIOLOGICAL SIGNALS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY | 2022-12-22 | — | — | US | disclosed |
| US-11473153-B2 | Device and methods of using device for separation of bacteria from complex samples | UNIVERSITY OF MARYLAND, COLLEGE PARK (US) | 2022-10-18 | — | — | US | disclosed |
| US-20220304313-A1 | METHODS FOR DEGRADING AHL SIGNALING MOLECULES OR PREVENTING PLANT DISEASE CAUSED THEREBY | SOUTH CHINA AGRICULTURAL UNIVERSITY (CN) | 2022-09-29 | — | — | US | disclosed |
| CN-112986420-B | Method for detecting microbial aggregate quorum sensing effect molecules by UPLC-MS/MS method | 军事科学院军事医学研究院环境医学与作业医学研究所 | 2022-09-13 | — | — | CN | disclosed |
| US-20220281816-A1 | DISCOVERY, TOTAL SYNTHESIS, AND BIOACTIVITY OF DOSCADENAMIDES | University of Florida Research Foundation, Incorporation (US) | 2022-09-08 | — | — | US | disclosed |
| CN-113322269-B | Biosensor based on bacterial population density sensing protein LuxR and application thereof | 中国人民解放军军事科学院军事医学研究院 | 2022-08-09 | — | — | CN | disclosed |
| CN-113322269-B | Biosensor based on bacterial population density sensing protein LuxR and application thereof | 中国人民解放军军事科学院军事医学研究院 | 2022-08-09 | — | — | CN | disclosed |
| CN-114634891-A | Bacillus belgii ZH3 and application thereof | 厦门萤星海科技有限公司 | 2022-06-17 | — | — | CN | disclosed |
| US-11357786-B2 | Synthetic disugar hydrocarbons as natural analogs to control microbial behaviors | SYRACUSE UNIVERSITY (US) | 2022-06-14 | — | — | US | disclosed |
| CN-114145303-B | Application of benzothiazole compound in preparation of agrobacterium tumefaciens quorum sensing inhibitor | 华南农业大学 | 2022-05-31 | — | — | CN | disclosed |
| US-20220160680-A1 | MICROORGANISM MIXTURES, MOLECULES DERIVED THEREFROM, AND METHODS OF USE THEREOF | B. G. NEGEV TECHNOLOGIES AND APPLICATIONS LTD., AT BEN-GURION UNIVERSITY (IL) | 2022-05-26 | — | — | US | disclosed |
| US-20220154156-A1 | PROTEINS AND METHODS FOR DISRUPTING BACTERIAL COMMUNICATION | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2022-05-19 | — | — | US | disclosed |
| EP-3983535-A1 | STABILIZED MUTANTS OF QUORUM QUENCHING LACTONASE AND USE THEREOF IN TREATMENT OF PATHOGENS | Migal Galilee Research Institute Ltd. (IL) | 2022-04-20 | — | — | EP | disclosed |
| CN-114302959-A | Stable mutants of quorum sensing quenched lactonases and their use in the treatment of pathogens | 米加尔-加利里研究院有限公司 | 2022-04-08 | — | — | CN | disclosed |
| CN-114145303-A | Application of benzothiazole compound in preparation of agrobacterium tumefaciens quorum sensing inhibitor | 华南农业大学 | 2022-03-08 | — | — | CN | disclosed |
| CN-112043697-B | Application of benzothiazole compound as quorum sensing inhibitor in treatment of bacterial diseases | 华南农业大学 | 2022-02-22 | — | — | CN | disclosed |
| CN-114057284-A | Device and method for improving salt impact resistance of anaerobic ammonia oxidation particle system based on quorum sensing effect | 北京工业大学 | 2022-02-18 | — | — | CN | disclosed |
| CN-114057284-A | Device and method for improving salt impact resistance of anaerobic ammonia oxidation particle system based on quorum sensing effect | 北京工业大学 | 2022-02-18 | — | — | CN | disclosed |
| CN-112042648-B | Methyl cinnamate as quorum sensing inhibitor and application thereof in treating bacterial diseases | 华南农业大学 | 2022-01-25 | — | — | CN | disclosed |
| US-20210023108-A1 | SYNTHETIC DISUGAR HYDROCARBONS AS NATURAL ANALOGS TO CONTROL MICROBIAL BEHAVIORS | SYRACUSE UNIVERSITY (US) | 2021-01-28 | — | — | US | disclosed |
| US-10702497-B2 | Use of acyl-homoserine lactone derivatives as anti-thrombotic agents | THE UNIVERSITY OF TOLEDO (US) | 2020-07-07 | — | — | US | disclosed |
| US-20190282597-A1 | SYNTHETIC DISUGAR HYDROCARBONS AS NATURAL ANALOGS TO CONTROL MICROBIAL BEHAVIORS | SYRACUSE UNIVERSITY (US) | 2019-09-19 | — | — | US | disclosed |
| US-20190111023-A1 | USE OF ACYL-HOMOSERINE LACTONE DERIVATIVES AS ANTI-THROMBOTIC AGENTS | THE UNIVERSITY OF TOLEDO (US) | 2019-04-18 | — | — | US | disclosed |
| EP-2311849-B1 | Specific binding agents of human angiopoietin-2 | AMGEN INC (US) | 2017-08-16 | — | — | EP | disclosed |
| CN-107012109-A | Applications of the signaling molecule C6 AHL in Phage Infection Escherichia coli are suppressed | 昆明理工大学 | 2017-08-04 | — | — | CN | disclosed |
| US-20170014437-A1 | SYNTHETIC DISUGAR HYDROCARBONS AS NATURAL ANALOGS TO CONTROL MICROBIAL BEHAVIORS | SYRACUSE UNIVERSITY (US) | 2017-01-19 | — | — | US | disclosed |
| US-9534032-B2 | Thrombopoietic compounds | AMGEN INC. (US) | 2017-01-03 | — | — | US | disclosed |
| US-20160176926-A1 | PEPTIDES AND RELATED MOLECULES THAT BIND TO TALL-1 | AMGEN INC (US) | 2016-06-23 | — | — | US | disclosed |
| CN-105530949-A | Myostatin antagonism in human subjects | AMGEN INC | 2016-04-27 | — | — | CN | disclosed |
| US-20160038588-A1 | Myostatin Antagonism in Human Subjects | AMGEN INC (US) | 2016-02-11 | — | — | US | disclosed |
| EP-2968463-A1 | MYOSTATIN ANTAGONISM IN HUMAN SUBJECTS | Amgen Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| US-9200040-B2 | Specific binding agents of human angiopoietin-2 | AMGEN INC. (US) | 2015-12-01 | — | — | US | disclosed |
| WO-2015153961-A1 | SYNTHETIC DISUGAR HYDROCARBONS AS NATURAL ANALOGOS TO CONTROL MICROBIAL BEHAVIORS | LUK YAN-YEUNG (US) | 2015-10-08 | — | — | WO | disclosed |
| US-9145450-B2 | Thrombopoietic compounds | AMGEN INC. (US) | 2015-09-29 | — | — | US | disclosed |
| US-9139645-B2 | Peptides and related molecules that bind to TALL-1 | AMGEN INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-20150175687-A1 | MYOSTATIN BINDING AGENTS | AMGEN INC. | 2015-06-25 | — | — | US | disclosed |
| EP-2845864-A2 | Peptides and related molecules that bind to TALL - 1 | Amgen, Inc (US) | 2015-03-11 | — | — | EP | disclosed |
| US-20150024431-A1 | THROMBOPOIETIC COMPOUNDS | AMGEN INC. (US) | 2015-01-22 | — | — | US | disclosed |
| US-8920798-B2 | Myostatin binding agents, nucleic acids encoding the same, and methods of treatment | AMGEN INC. (US) | 2014-12-30 | — | — | US | disclosed |
| EP-1921088-B1 | Peptides and related molecules that bind to tall-1 | AMGEN INC (US) | 2014-10-08 | — | — | EP | disclosed |
| US-20140294866-A1 | Uses of Myostatin Antagonists | AMGEN INC. | 2014-10-02 | — | — | US | disclosed |
| US-20140275479-A1 | SPECIFIC BINDING AGENTS OF HUMAN ANGIOPOEITIN-2 | AMGEN INC. (US) | 2014-09-18 | — | — | US | disclosed |
| WO-2014144903-A1 | MYOSTATIN ANTAGONISM IN HUMAN SUBJECTS | AMGEN INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| US-20140234334-A1 | PEPTIDES AND RELATED MOLECULES THAT BIND TO TALL-1 | AMGEN INC. (US) | 2014-08-21 | — | — | US | disclosed |
| US-20140234945-A1 | TRANSTHYRETIN VARIANTS | AMGEN INC. (US) | 2014-08-21 | — | — | US | disclosed |
| US-20140221210-A1 | ACYL-HOMOSERINE LACTONE DERIVATIVES FOR IMPROVING PLANT YIELD | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-08-07 | — | — | US | disclosed |
| US-20140221210-A1 | ACYL-HOMOSERINE LACTONE DERIVATIVES FOR IMPROVING PLANT YIELD | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-08-07 | — | — | US | disclosed |
| US-8748571-B2 | Thrombopoietic compounds | AMGEN INC. (US) | 2014-06-10 | — | — | US | disclosed |
| EP-2319928-B9 | Dimeric thrombopoietin peptide mimetics binding to MP1 receptor and having thrombopoietic activity | KIRIN AMGEN INC (US) | 2014-04-16 | — | — | EP | disclosed |
| US-8663927-B2 | Systems and methods for diagnosis and monitoring of bacteria-related conditions | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2014-03-04 | — | — | US | disclosed |
| US-8633153-B2 | Transthyretin variants | AMGEN INC. (US) | 2014-01-21 | — | — | US | disclosed |
| EP-2679235-A2 | Peptides and related molecules that modulate nerve growth factor activity | Amgen Inc. (US) | 2014-01-01 | — | — | EP | disclosed |
| US-8618044-B2 | Thrombopoietic compounds | AMGEN INC. (US) | 2013-12-31 | — | — | US | disclosed |
| US-20130316448-A1 | PEPTIDES AND RELATED MOLECULES THAT MODULATE NERVE GROWTH FACTOR ACTIVITY | AMGEN INC. (US) | 2013-11-28 | — | — | US | disclosed |
| EP-2666473-A1 | Peptides and related molecules that modulate nerve growth factor activity | AMGEN INC. (US) | 2013-11-27 | — | — | EP | disclosed |
| EP-2666474-A1 | Peptides and related molecules that modulate nerve growth factor activity | Amgen Inc. (US) | 2013-11-27 | — | — | EP | disclosed |
| US-20130230515-A1 | MYOSTATIN BINDING AGENTS | AMGEN INC. (US) | 2013-09-05 | — | — | US | disclosed |
| US-8513396-B2 | Peptides and related molecules that modulate nerve growth factor activity | AMGEN INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-8507426-B2 | Peptides and related molecules that bind to TALL-1 | AMGEN, INC. (US) | 2013-08-13 | — | — | US | disclosed |
| US-20130158234-A1 | SPECIFIC BINDING AGENTS OF HUMAN ANGIOPOIETIN-2 | AMGEN INC. (US) | 2013-06-20 | — | — | US | disclosed |
| EP-1439852-B1 | PEPTIDES AND RELATED COMPOUNDS HAVING THROMBOPOIETIC ACTIVITY | AMGEN INC (US) | 2013-05-29 | — | — | EP | disclosed |
| EP-2319928-B1 | Dimeric thrombopoietin peptide mimetics binding to MP1 receptor and having thrombopoietic activity | KIRIN AMGEN INC (US) | 2013-03-27 | — | — | EP | disclosed |
| WO-2013034621-A1 | ACYL-HOMOSERINE LACTONE DERIVATIVES FOR IMPROVING PLANT YIELD | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-03-14 | — | — | WO | disclosed |
| EP-2316845-B1 | Specific binding agents of human angiopoietin-2 | AMGEN INC (US) | 2013-01-16 | — | — | EP | disclosed |
| EP-1496926-B1 | USE OF TRANSTHYRETIN PEPTIDE/PROTEIN FUSIONS TO INCREASE THE SERUM HALF-LIFE OF PHARMACOLOGICALLY ACTIVE PEPTIDES/PROTEINS | AMGEN INC (US) | 2012-12-19 | — | — | EP | disclosed |
| EP-1144454-B2 | MODIFIED PEPTIDES AS THERAPEUTIC AGENTS | AMGEN INC (US) | 2012-12-12 | — | — | EP | disclosed |
| EP-1545581-B1 | Peptides that modulate nerve growth factor (NGF) activity, their compositions and use | AMGEN INC (US) | 2012-10-24 | — | — | EP | disclosed |
| EP-2070944-B1 | Specific binding agents of human angiopoietin-2 | AMGEN INC (US) | 2012-09-26 | — | — | EP | disclosed |
| US-8269024-B2 | Compounds and methods for modulating communication and virulence in quorum sensing bacteria | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2012-09-18 | — | — | US | disclosed |
| US-8269024-B2 | Compounds and methods for modulating communication and virulence in quorum sensing bacteria | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2012-09-18 | — | — | US | disclosed |
| US-20120208760-A1 | THROMBOPOIETIC COMPOUNDS | AMGEN INC. (US) | 2012-08-16 | — | — | US | disclosed |
| US-20120141499-A1 | SPECIFIC BINDING AGENTS OF HUMAN ANGIOPOIETIN-2 | OLINER JONATHAN DANIEL (US) | 2012-06-07 | — | — | US | disclosed |
| EP-1783222-B1 | Dimeric thrombopoietin peptide mimetics binding to MPL receptor and having thrombopoietic activity. | KIRIN AMGEN INC (US) | 2012-06-06 | — | — | EP | disclosed |
| US-20120129771-A1 | PEPTIDES AND RELATED MOLECULES THAT MODULATE NERVE GROWTH FACTOR ACTIVITY | AMGEN INC. (US) | 2012-05-24 | — | — | US | disclosed |
| US-20120083442-A1 | MYOSTATIN BINDING AGENTS | AMGEN INC. (US) | 2012-04-05 | — | — | US | disclosed |
| EP-2292655-B1 | Peptides and related molecules that bind to tall-1 | AMGEN INC (US) | 2012-03-14 | — | — | EP | disclosed |
| US-8129331-B2 | Specific binding agents of human angiopoietin-2 | AMGEN INC. (US) | 2012-03-06 | — | — | US | disclosed |
| US-8124724-B2 | Peptides and related molecules that modulate nerve growth factor activity | AMGEN INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-20120034657-A1 | THROMBOPOIETIC COMPOUNDS | AMGEN INC. (US) | 2012-02-09 | — | — | US | disclosed |
| US-8071538-B2 | Method of increasing muscle mass by administering a myostatin binding agent | AMGEN INC. | 2011-12-06 | — | — | US | disclosed |
| EP-1615952-B1 | METHODS OF TREATMENT OF INFLAMMATORY DISEASES USING SPECIFIC BINDING AGENTS OF HUMAN ANGIOPOIETIN-2 | AMGEN INC (US) | 2011-11-02 | — | — | EP | disclosed |
| US-8044174-B2 | Peptides and polypeptides which may be used to increase platelets or platelet precursors (e.g., megakaryocytes) in a mammal | AMGEN INC. (US) | 2011-10-25 | — | — | US | disclosed |
| US-20110229472-A1 | Peptides and Related Compounds Having Thrombopoietic Activity | AMGEN INC. (US) | 2011-09-22 | — | — | US | disclosed |
| US-7994117-B2 | Thrombopoietic compounds | AMGEN INC. (US) | 2011-08-09 | — | — | US | disclosed |
| EP-2332974-A2 | Osteoprotegerin | Amgen, Inc (US) | 2011-06-15 | — | — | EP | disclosed |
| EP-2319928-A1 | Dimeric thrombopoietin peptide mimetics binding to MP1 receptor and having thrombopoietic activity | Kirin-Amgen, Inc. (US) | 2011-05-11 | — | — | EP | disclosed |
| EP-2316845-A1 | Specific binding agents of human angiopoietin-2 | Amgen Inc. (US) | 2011-05-04 | — | — | EP | disclosed |
| EP-2311849-A1 | Specific binding agents of human angiopoietin-2 | Amgen, Inc (US) | 2011-04-20 | — | — | EP | disclosed |
| US-7928074-B2 | Using interleukin-1 specfic immunoglobulin fusion and tumor necrosis factor inhibitors to treat inflammatory and/or autoimmune disorders | AMGEN INC. (US) | 2011-04-19 | — | — | US | disclosed |
| US-7928075-B2 | Binding agents which inhibit myostatin | AMGEN INC. (US) | 2011-04-19 | — | — | US | disclosed |
| US-20110071077-A1 | Thrombopoietic Compounds | AMGEN INC. (US) | 2011-03-24 | — | — | US | disclosed |
| EP-2298331-A2 | Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins | Amgen, Inc (US) | 2011-03-23 | — | — | EP | disclosed |
| EP-2292655-A1 | Peptides and related molecules that bind to tall-1 | Amgen SF, LLC (US) | 2011-03-09 | — | — | EP | disclosed |
| EP-1581649-B1 | BINDING AGENTS WHICH INHIBIT MYOSTATIN | AMGEN INC (US) | 2011-01-26 | — | — | EP | disclosed |
| US-20110008375-A1 | Uses of Myostatin Antagonists | AMGEN INC. | 2011-01-13 | — | — | US | disclosed |
| EP-2272864-A2 | Binding agents which inhibit myostatin | AMGEN INC. (US) | 2011-01-12 | — | — | EP | disclosed |
| US-20100330072-A1 | Myostatin binding agents | AMGEN INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100305182-A1 | COMPOUNDS AND METHODS FOR MODULATING COMMUNICATION AND VIRULENCE IN QUORUM SENSING BACTERIA | BLACKWELL HELEN E | 2010-12-02 | — | — | US | disclosed |
| US-20100305182-A1 | COMPOUNDS AND METHODS FOR MODULATING COMMUNICATION AND VIRULENCE IN QUORUM SENSING BACTERIA | BLACKWELL HELEN E | 2010-12-02 | — | — | US | disclosed |
| US-20100298229-A1 | OSTEOPROTEGERIN | AMGEN INC. | 2010-11-25 | — | — | US | disclosed |
| US-20100291566-A1 | SYSTEMS AND METHODS FOR DIAGNOSIS AND MONITORING OF BACTERIA-RELATED CONDITIONS | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2010-11-18 | — | — | US | disclosed |
| US-20100286060-A1 | SPECIFIC BINDING AGENTS OF HUMAN ANGIOPOEITIN-2 | AMGEN INC. (US) | 2010-11-11 | — | — | US | disclosed |
| US-7803923-B2 | Growth differentiation factor-8 binding agents for treatment of metabolic, nervous system, muscular, bone , urogenital and inflammatory disorders; for treating muscle-wasting disorders and metabolic disorders including diabetes and obesity | AMGEN INC. (US) | 2010-09-28 | — | — | US | disclosed |
| US-20100240590-A1 | PEPTIDES AND RELATED MOLECULES THAT BIND TO TALL-1 | AMGEN INC. | 2010-09-23 | — | — | US | disclosed |
| US-20100240582-A1 | Peptides and related molecules that modulate nerve growth factor activity | AMGEN INC. | 2010-09-23 | — | — | US | disclosed |
| US-7790674-B2 | Methods of treatment using specific binding agents of human angiopoietin-2 | AMGEN INC. (US) | 2010-09-07 | — | — | US | disclosed |
| US-20100216835-A1 | Method For Modulating Microbial Quorum Sensing | HANDELSMAN JO E | 2010-08-26 | — | — | US | disclosed |
| US-7771965-B2 | Tumor endothelial marker 5α molecules and uses thereof | AMGEN INC. (US) | 2010-08-10 | — | — | US | disclosed |
| EP-1124961-B9 | THROMBOPOIETIC COMPOUNDS | KIRIN AMGEN INC (US) | 2010-07-21 | — | — | EP | disclosed |
| US-7737111-B2 | Tumor necrosis factors; cytokines; immunoglobulins; autoimmune diseases | AMGEN, INC. (US) | 2010-06-15 | — | — | US | disclosed |
| US-7723499-B2 | polynucleotides that code for polypeptides comprising amino acid sequences that preferentially recognize and bind to angiopoietins | AMGEN INC. (US) | 2010-05-25 | — | — | US | disclosed |
| EP-2157097-A1 | Specific binding agents of human angiopoietin-2 | Amgen, Inc. (US) | 2010-02-24 | — | — | EP | disclosed |
| US-7666839-B2 | Administering peptibodies, i.e., peptides fused to other molecules such as an Fc domain of an antibody, where the peptide moiety specifically binds to Ang-2 ( angiopoietin-2); antiinflammatory agent; antirheumatic agent | AMGEN INC. (US) | 2010-02-23 | — | — | US | disclosed |
| US-7666831-B2 | Administering peptibodies, i.e., peptides fused to other molecules such as an Fc domain of an antibody, where the peptide moiety specifically binds to Ang-2 ( angiopoietin-2); antiinflammatory agent; antirheumatic agent | AMGEN INC. (US) | 2010-02-23 | — | — | US | disclosed |
| US-7666832-B2 | Administering peptibodies, i.e., peptides fused to other molecules such as an Fc domain of an antibody, where the peptide moiety specifically binds to Ang-2 ( angiopoietin-2); antiinflammatory agent; antirheumatic agent | AMGEN INC. (US) | 2010-02-23 | — | — | US | disclosed |
| US-7642285-B2 | Compounds and methods for modulating communication and virulence in quorum sensing bacteria | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2010-01-05 | — | — | US | disclosed |
| US-7642285-B2 | Compounds and methods for modulating communication and virulence in quorum sensing bacteria | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2010-01-05 | — | — | US | disclosed |
| US-7632922-B1 | Osteoprotegerin | AMGEN, INC. (US) | 2009-12-15 | — | — | US | disclosed |
| EP-1434791-B1 | SPECIFIC BINDING AGENTS OF HUMAN ANGIOPOIETIN-2 | AMGEN INC (US) | 2009-10-07 | — | — | EP | disclosed |
| US-20090227517-A1 | Growth differentiation factor-8 binding agents for treatment of metabolic, nervous system, muscular, bone , urogenital and inflammatory disorders; for treating muscle-wasting disorders and metabolic disorders including diabetes and obesity | AMGEN INC. (US) | 2009-09-10 | — | — | US | disclosed |
| US-20090220491-A1 | Binding agents which inhibit myostatin | AMGEN INC. (US) | 2009-09-03 | — | — | US | disclosed |
| US-7579316-B2 | Administering CTLA-4, tumor necrosis factor inhibitors, and immunogens | AMGEN INC. (US) | 2009-08-25 | — | — | US | disclosed |
| EP-1385882-B9 | PEPTIDES AND RELATED MOLECULES THAT BIND TO TALL-1 | AMGEN INC (US) | 2009-08-12 | — | — | EP | disclosed |
| US-20090191624-A1 | Use of transthyretin peptide/protein fussions to increase the serum half-life of pharmacologically active peptides/proteins | AMGEN INC. (US) | 2009-07-30 | — | — | US | disclosed |
| US-20090186822-A1 | Thrombopoietic Compounds | AMGEN INC. (US) | 2009-07-23 | — | — | US | disclosed |
| EP-1684791-A4 | COMPOSITIONS AND METHODS TO MODULATE AN IMMUNE RESPONSE TO AN IMMUNOGENIC THERAPEUTIC AGENT | AMGEN INC (US) | 2009-07-01 | — | — | EP | disclosed |
| EP-2070944-A1 | Specific binding agents of human angiopoietin-2 | Amgen Inc. (US) | 2009-06-17 | — | — | EP | disclosed |
| US-7511012-B2 | Growth differentiation factor -8 binding agents for treatment of metabolic, nervous system, muscular, bone , urogenital and inflammatory disorders | AMGEN INC. (US) | 2009-03-31 | — | — | US | disclosed |
| US-20090054323-A1 | Ang-2 inhibitor peptides; use treating tumors, eye disorders, bone disorders, psoriasis; angiogenesis inhibitors; amino acid sequence WDPWT | AMGEN INC. (US) | 2009-02-26 | — | — | US | disclosed |
| US-20090053242-A1 | Thrombopoietic compounds | AMGEN INC. (US) | 2009-02-26 | — | — | US | disclosed |
| US-7488590-B2 | Fusion of Fc domains with biologically active peptides; selecting peptide that modulates the activity of AGP-3, preparing a gene construct; expressing the pharmacologically active compound in which an Fc domain is covalently linked to peptide | AMGEN INC. (US) | 2009-02-10 | — | — | US | disclosed |
| US-20090011497-A1 | Peptides and related compounds having thrombopoietic activity | AMGEN INC. | 2009-01-08 | — | — | US | disclosed |
| US-20080279862-A1 | Combination Therapy with Co-Stimulatory Factors | AMGEN INC. | 2008-11-13 | — | — | US | disclosed |
| EP-1990415-A1 | Osteoprotegerin | Amgen Inc. (US) | 2008-11-12 | — | — | EP | disclosed |
| EP-1986677-A2 | THROMBOPOIETIC COMPOUNDS | Amgen Inc. (US) | 2008-11-05 | — | — | EP | disclosed |
| EP-1581649-A4 | BINDING AGENTS WHICH INHIBIT MYOSTATIN | AMGEN INC (US) | 2008-10-08 | — | — | EP | disclosed |
| EP-0784093-B1 | Osteoprotegerin | AMGEN INC (US) | 2008-10-01 | — | — | EP | disclosed |
| EP-1968621-A2 | USES OF MYOSTATIN ANTAGONISTS | Amgen Inc. (US) | 2008-09-17 | — | — | EP | disclosed |
| WO-2008087454-A2 | POLYMER INHIBITORS OF QUORUM SENSING | UNIVERSITY OF KENT (GB) | 2008-07-24 | — | — | WO | disclosed |
| US-7384639-B2 | Methods of treating or preventing an infectious disease using an immunogenic conjugate of a gram-negative bacterial autoinducer molecule | UNIVERSITY OF ROCHESTER (US) | 2008-06-10 | — | — | US | disclosed |
| US-7384639-B2 | Methods of treating or preventing an infectious disease using an immunogenic conjugate of a gram-negative bacterial autoinducer molecule | UNIVERSITY OF ROCHESTER (US) | 2008-06-10 | — | — | US | disclosed |
| EP-1921088-A2 | Peptides and related molecules that bind to tall-1 | Amgen Inc. (US) | 2008-05-14 | — | — | EP | disclosed |
| US-7371559-B2 | Peptides and related molecules that modulate nerve growth factor activity | AMGEN INC. (US) | 2008-05-13 | — | — | US | disclosed |
| CN-100384880-C | Modified peptides as therapeutic agents | AMGEN INC (US) | 2008-04-30 | — | — | CN | disclosed |
| CN-100384879-C | Modified peptides as therapeutic agents | AMGEN INC (US) | 2008-04-30 | — | — | CN | disclosed |
| US-7332474-B2 | Peptides and related compounds having thrombopoietic activity | AMGEN INC. (US) | 2008-02-19 | — | — | US | disclosed |
| EP-1144454-B1 | MODIFIED PEPTIDES AS THERAPEUTIC AGENTS | AMGEN INC (US) | 2007-12-12 | — | — | EP | disclosed |
| EP-1439852-A4 | PEPTIDES AND RELATED COMPOUNDS HAVING THROMBOPOIETIC ACTIVITY | AMGEN INC (US) | 2007-12-05 | — | — | EP | disclosed |
| EP-1385882-B1 | PEPTIDES AND RELATED MOLECULES THAT BIND TO TALL-1 | AMGEN INC (US) | 2007-10-10 | — | — | EP | disclosed |
| US-20070231839-A1 | Methods of treating or preventing an infectious disease using an immunogenic conjugate of a gram-negative bacterial autoinducer molecule or antibodies that immunospecifically bind a gram-negative bacterial autoinducer molecule | UNIVERSITY OF ROCHESTER (US) | 2007-10-04 | — | — | US | disclosed |
| US-20070231839-A1 | Methods of treating or preventing an infectious disease using an immunogenic conjugate of a gram-negative bacterial autoinducer molecule or antibodies that immunospecifically bind a gram-negative bacterial autoinducer molecule | UNIVERSITY OF ROCHESTER (US) | 2007-10-04 | — | — | US | disclosed |
| US-20070225221-A1 | Methods of treatment using specific binding agents of human angiopoietin-2 | AMGEN INC. (US) | 2007-09-27 | — | — | US | disclosed |
| EP-1578782-A4 | COMBINATION THERAPY WITH CO-STIMULATORY FACTORS | AMGEN INC (US) | 2007-09-12 | — | — | EP | disclosed |
| US-7259137-B2 | Tumor necrosis factors; cytokines; immunoglobulins; autoimmune diseases | AMGEN INC. (US) | 2007-08-21 | — | — | US | disclosed |
| WO-2007087428-A2 | THROMBOPOIETIC COMPOUNDS | AMGEN INC. (US) | 2007-08-02 | — | — | WO | disclosed |
| US-20070149458-A1 | Uses of myostatin antagonists | AMGEN INC. (US) | 2007-06-28 | — | — | US | disclosed |
| US-20070142295-A1 | Thrombopoietic compounds | AMGEN INC. (US) | 2007-06-21 | — | — | US | disclosed |
| WO-2007067616-A2 | USES OF MYOSTATIN ANTAGONISTS | AMGEN INC (US) | 2007-06-14 | — | — | WO | disclosed |
| US-20070110680-A1 | Methods and compositions for controlling biofilm development | MONTANA STATE UNIVERSITY (US) | 2007-05-17 | — | — | US | disclosed |
| EP-1783222-A1 | Dimeric thrombopoietin peptide mimetics binding to MP1 receptor and having thrombopoietic activity. | Amgen Inc. (US) | 2007-05-09 | — | — | EP | disclosed |
| US-20070093418-A1 | Methods of treatment using specific binding agents of human angiopoietin-2 | AMGEN INC. (US) | 2007-04-26 | — | — | US | disclosed |
| US-20070093419-A1 | Methods of treatment using specific binding agents of human angiopoietin-2 | AMGEN INC. (US) | 2007-04-26 | — | — | US | disclosed |
| EP-1777234-A2 | Methods of treatment of inflammatory diseases using specific binding agents of human angiopoietin - 2 | Amgen Inc. (US) | 2007-04-25 | — | — | EP | disclosed |
| CN-1310948-C | Modified peptides as therapeutic agents | AMGEN INC (US) | 2007-04-18 | — | — | CN | disclosed |
| US-7205275-B2 | Methods of treatment using specific binding agents of human angiopoietin-2 | AMGEN INC. (US) | 2007-04-17 | — | — | US | disclosed |
| US-20070072801-A1 | Administering peptibodies, i.e., peptides fused to other molecules such as an Fc domain of an antibody, where the peptide moiety specifically binds to Ang-2 ( angiopoietin-2); antiinflammatory agent; antirheumatic agent | AMGEN INC. (US) | 2007-03-29 | — | — | US | disclosed |
| EP-1767544-A2 | Methods of treatment of inflammatory diseases using specific binding agents of human angiopoietin - 2 | Amgen Inc. (US) | 2007-03-28 | — | — | EP | disclosed |
| EP-1764370-A2 | Methods of treatment of inflammatory diseases using specific binding agents of human angiopoietin - 2 | Amgen Inc. (US) | 2007-03-21 | — | — | EP | disclosed |
| US-20070060643-A1 | Autoinducer compounds | MONTANA STATE UNIVERSITY (US) | 2007-03-15 | — | — | US | disclosed |
| US-7189827-B2 | Modified peptides as therapeutic agents | AMGEN INC. (US) | 2007-03-13 | — | — | US | disclosed |
| US-7186810-B2 | Modified peptides as therapeutic agents | AMGEN INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-20070049532-A1 | Modified peptides as therapeutic agents | AMGEN INC. | 2007-03-01 | — | — | US | disclosed |
| CN-1908014-A | Modified peptides as therapeutic agents | AMGEN INC (US) | 2007-02-07 | — | — | CN | disclosed |
| US-7169905-B2 | Modified peptides as therapeutic agents | AMGEN INC. (US) | 2007-01-30 | — | — | US | disclosed |
| US-7166707-B2 | Identifying peptide mimetic for treatment and prevention of tumors and autoimune diseases | AMGEN INC. (US) | 2007-01-23 | — | — | US | disclosed |
| US-20070010662-A1 | VGF fusion polypeptides | AMGEN INC. (US) | 2007-01-11 | — | — | US | disclosed |
| EP-1124961-B1 | THROMBOPOIETIC COMPOUNDS | AMGEN INC (US) | 2006-12-13 | — | — | EP | disclosed |
| US-7138370-B2 | Anticancer agents; skin disorders; antiinflamamtory agents; antiarthritic agents | AMGEN INC. (US) | 2006-11-21 | — | — | US | disclosed |
| US-20060234307-A1 | Modified peptides as therapeutic agents | AMGEN INC. | 2006-10-19 | — | — | US | disclosed |
| EP-0994961-B1 | HOMOSERINE LACTONES BIOFILM REGULATING COMPOUNDS AND THEIR METHODS OF USE | UNIV MONTANA STATE (US) | 2006-10-18 | — | — | EP | disclosed |
| EP-1496926-A4 | USE OF TRANSTHYRETIN PEPTIDE/PROTEIN FUSIONS TO INCREASE THE SERUM HALF-LIFE OF PHARMACOLOGICALLY ACTIVE PEPTIDES/PROTEINS | AMGEN INC (US) | 2006-10-18 | — | — | EP | disclosed |
| US-20060189531-A1 | Thrombopoietic compounds | AMGEN INC. (US) | 2006-08-24 | — | — | US | disclosed |
| US-7094394-B2 | Methods and compositions for controlling biofilm development | MONTANA STATE UNIVERSITY (US) | 2006-08-22 | — | — | US | disclosed |
| EP-1684791-A2 | COMPOSITIONS AND METHODS TO MODULATE AN IMMUNE RESPONSE TO AN IMMUNOGENIC THERAPEUTIC AGENT | Amgen Inc. (US) | 2006-08-02 | — | — | EP | disclosed |
| US-7078435-B2 | Autoinducer compounds | MONTANA STATE UNIVERSITY (US) | 2006-07-18 | — | — | US | disclosed |
| US-20060135431-A1 | Tumor necrosis factors; cytokines; immunoglobulins; autoimmune diseases | AMGEN INC. | 2006-06-22 | — | — | US | disclosed |
| US-20060122370-A1 | polynucleotides that code for polypeptides comprising amino acid sequences that preferentially recognize and bind to angiopoietins | AMGEN INC. | 2006-06-08 | — | — | US | disclosed |
| CN-1781945-A | Modified peptides as therapeutic agents | AMGEN INC (US) | 2006-06-07 | — | — | CN | disclosed |
| CN-1781946-A | Modified peptides as therapeutic agents | AMGEN INC (US) | 2006-06-07 | — | — | CN | disclosed |
| CN-1781947-A | Modified peptides as therapeutic agents | AMGEN INC (US) | 2006-06-07 | — | — | CN | disclosed |
| EP-1434791-A4 | SPECIFIC BINDING AGENTS OF HUMAN ANGIOPOIETIN-2 | AMGEN INC (US) | 2006-04-26 | — | — | EP | disclosed |
| CN-1746189-A | Modified peptides as therapeutic agents | AMGEN INC (US) | 2006-03-15 | — | — | CN | disclosed |
| CN-1746190-A | Modified peptides as therapeutic agents | AMGEN INC (US) | 2006-03-15 | — | — | CN | disclosed |
| US-7008924-B1 | VGF fusion polypeptides | AMGEN, INC. (US) | 2006-03-07 | — | — | US | disclosed |
| US-7005413-B1 | Combination therapy for conditions leading to bone loss | AMGEN INC. (US) | 2006-02-28 | — | — | US | disclosed |
| EP-1615952-A2 | METHODS OF TREATMENT OF INFLAMMATORY DISEASES USING SPECIFIC BINDING AGENTS OF HUMAN ANGIOPOIETIN-2 | Amgen Inc. (US) | 2006-01-18 | — | — | EP | disclosed |
| CN-1721447-A | Modified peptides as therapeutic agents | AMGEN INC (US) | 2006-01-18 | — | — | CN | disclosed |
| US-20050287152-A1 | Compositions and methods to modulate an immune response to an immunogenic therapeutic agent | AMGEN INC. | 2005-12-29 | — | — | US | disclosed |
| EP-1487269-A4 | AUTOINDUCER COMPOUNDS | UNIV MONTANA STATE (US) | 2005-12-21 | — | — | EP | disclosed |
| EP-1196442-B1 | VGF POLYPEPTIDES AND METHODS OF TREATING VGF-RELATED DISORDERS | AMGEN INC (US) | 2005-12-21 | — | — | EP | disclosed |
| US-20050222035-A1 | Peptides and related molecules that modulate nerve growth factor activity | AMGEN INC. | 2005-10-06 | — | — | US | disclosed |
| US-20050221331-A1 | Osteoprotegerin | AMGEN INC. | 2005-10-06 | — | — | US | disclosed |
| EP-1581649-A2 | BINDING AGENTS WHICH INHIBIT MYOSTATIN | Amgen, Inc. (US) | 2005-10-05 | — | — | EP | disclosed |
| EP-1578782-A2 | COMBINATION THERAPY WITH CO-STIMULATORY FACTORS | Amgen, Inc. (US) | 2005-09-28 | — | — | EP | disclosed |
| EP-1385882-A4 | PEPTIDES AND RELATED MOLECULES THAT BIND TO TALL-1 | AMGEN INC (US) | 2005-09-21 | — | — | EP | disclosed |
| EP-1578782-A3 | COMBINATION THERAPY WITH CO-STIMULATORY FACTORS | Amgen, Inc. (US) | 2005-09-01 | — | — | EP | disclosed |
| US-6919426-B2 | Peptides and related molecules that modulate nerve growth factor activity | AMGEN INC. (US) | 2005-07-19 | — | — | US | disclosed |
| US-20050147611-A1 | Combination therapy for conditions leading to bone loss | AMGEN INC. | 2005-07-07 | — | — | US | disclosed |
| EP-1545581-A1 | PEPTIDES AND RELATED MOLECULES THAT MODULATE NERVE GROWTH FACTOR ACTIVITY | AMGEN INC. (US) | 2005-06-29 | — | — | EP | disclosed |
| EP-1196188-B1 | VGF SELECTIVE MONOCLONAL ANTIBODIES AND THEIR USE FOR TREATING VGF-RELATED DISORDERS | AMGEN INC (US) | 2005-06-22 | — | — | EP | disclosed |
| US-20050123548-A1 | Modified peptides as therapeutic agents | AMGEN INC. | 2005-06-09 | — | — | US | disclosed |
| WO-2005044188-A2 | COMPOSITIONS AND METHODS TO MODULATE AN IMMUNE RESPONSE TO AN IMMUNOGENIC THERAPEUTIC AGENT | AMGEN INC. (US) | 2005-05-19 | — | — | WO | disclosed |
| US-20050080014-A1 | Peptides and polypeptides which may be used to increase platelets or platelet precursors (e.g., megakaryocytes) in a mammal | AMGEN INC. | 2005-04-14 | — | — | US | disclosed |
| US-20050049180-A1 | VGF polypeptides and methods of treating VGF-related disorders | AMGEN, INC. | 2005-03-03 | — | — | US | disclosed |
| US-6858581-B2 | Chemically-modified peptides, compositions, and methods of production and use | ARIZONA STATE UNIVERSITY (US) | 2005-02-22 | — | — | US | disclosed |
| EP-1496926-A1 | USE OF TRANSTHYRETIN PEPTIDE/PROTEIN FUSIONS TO INCREASE THE SERUM HALF-LIFE OF PHARMACOLOGICALLY ACTIVE PEPTIDES/PROTEINS | Amgen Inc. (US) | 2005-01-19 | — | — | EP | disclosed |
| US-6835809-B1 | Thrombopoietic compounds | AMGEN INC. | 2004-12-28 | — | — | US | disclosed |
| EP-1487269-A1 | AUTOINDUCER COMPOUNDS | Montana State University-Bozeman (US) | 2004-12-22 | — | — | EP | disclosed |
| US-20040254235-A1 | Autoinducer compounds | NATIONAL SCIENCE FOUNDATION | 2004-12-16 | — | — | US | disclosed |
| WO-2004092215-A2 | METHODS OF TREATMENT OF INFLAMMATORY DISEASES USING SPECIFIC BINDING AGENTS OF HUMAN ANGIOPOIETIN-2 | AMGEN INC. (US) | 2004-10-28 | — | — | WO | disclosed |
| US-20040208874-A1 | Combination therapy with co-stimulatory factors | AMGEN, INC. | 2004-10-21 | — | — | US | disclosed |
| US-20040181033-A1 | Growth differentiation factor -8 binding agents for treatment of metabolic, nervous system, muscular, bone , urogenital and inflammatory disorders | AMGEN, INC. | 2004-09-16 | — | — | US | disclosed |
| EP-0977859-B1 | THE NEUROTROPHIC FACTOR NNT-1 | AMGEN INC (US) | 2004-08-11 | — | — | EP | disclosed |
| EP-1439852-A1 | PEPTIDES AND RELATED COMPOUNDS HAVING THROMBOPOIETIC ACTIVITY | Amgen Inc. (US) | 2004-07-28 | — | — | EP | disclosed |
| WO-2004060911-A2 | COMBINATION THERAPY WITH CO-STIMULATORY FACTORS | AMGEN INC. (US) | 2004-07-22 | — | — | WO | disclosed |
| WO-2004058988-A2 | BINDING AGENTS WHICH INHIBIT MYOSTATIN | AMGEN, INC. (US) | 2004-07-15 | — | — | WO | disclosed |
| EP-1434791-A2 | SPECIFIC BINDING AGENTS OF HUMAN ANGIOPOIETIN-2 | Amgen, Inc. (US) | 2004-07-07 | — | — | EP | disclosed |
| US-6756404-B2 | PREVENTION INFECTIONS | THE RESEARCH & DEVELOPMENT INSTITUTE, INC. | 2004-06-29 | — | — | US | disclosed |
| US-20040121959-A1 | Peptides and related molecules that modulate nerve growth factor activity | AMGEN INC. | 2004-06-24 | — | — | US | disclosed |
| US-6733753-B2 | ANTIINFLAMMATORY PROTEIN | AMGEN INC. | 2004-05-11 | — | — | US | disclosed |
| US-20040087778-A1 | Modified peptides as therapeutic agents | AMGEN INC. | 2004-05-06 | — | — | US | disclosed |
| US-20040077022-A1 | Modified peptides as therapeutic agents | FEIGE ULRICH (US) | 2004-04-22 | — | — | US | disclosed |
| US-20040071712-A1 | Modified peptides as therapeutic agents | AMGEN INC. | 2004-04-15 | — | — | US | disclosed |
| WO-2004026329-A1 | PEPTIDES AND RELATED MOLECULES THAT MODULATE NERVE GROWTH FACTOR ACTIVITY | AMGEN INC. (US) | 2004-04-01 | — | — | WO | disclosed |
| US-20040057953-A1 | Modified peptides as therapeutic agents | AMGEN INC. | 2004-03-25 | — | — | US | disclosed |
| US-20040053845-A1 | Modified peptides as therapeutic agents | AMGEN INC. | 2004-03-18 | — | — | US | disclosed |
| US-20040044188-A1 | Modified peptides as therapeutic agents | AMGEN INC. | 2004-03-04 | — | — | US | disclosed |
| EP-1385882-A2 | PEPTIDES AND RELATED MOLECULES THAT BIND TO TALL-1 | Amgen, Inc. (US) | 2004-02-04 | — | — | EP | disclosed |
| US-20030236193-A1 | Methods of treatment using specific binding agents of human angiopoietin-2 | AMGEN INC. | 2003-12-25 | — | — | US | disclosed |
| US-20030229023-A1 | Anticancer agents; skin disorders; antiinflamamtory agents; antiarthritic agents | AMGEN INC. | 2003-12-11 | — | — | US | disclosed |
| US-6660843-B1 | Fusion of Fc domains with biologically active peptides | AMGEN INC. | 2003-12-09 | — | — | US | disclosed |
| US-20030207827-A1 | OSTEOPROTEGERIN | BOYLE WILLIAM J (US) | 2003-11-06 | — | — | US | disclosed |
| WO-2003086444-A1 | USE OF TRANSTHYRETIN PEPTIDE/PROTEIN FUSIONS TO INCREASE THE SERUM HALF-LIFE OF PHARMACOLOGICALLY ACTIVE PEPTIDES/PROTEINS | AMGEN INC. (US) | 2003-10-23 | — | — | WO | disclosed |
| US-20030195154-A1 | Comprises mimetics of erythropoietin, thrombopoietin, and glucagon-like peptide conjugated to polymer | AMGEN INC. | 2003-10-16 | — | — | US | disclosed |
| US-6632638-B1 | As a fusion partner; useful for suppressing the competing aggregation pathway and facilitating proper folding; escherichia coli | AMGEN, INC. | 2003-10-14 | — | — | US | disclosed |
| US-20030191056-A1 | Immobilization onto polyoxyethylene glycol | AMGEN INC. | 2003-10-09 | — | — | US | disclosed |
| WO-2003077653-A1 | AUTOINDUCER COMPOUNDS | MONTANA STATE UNIVERSITY-BOZEMAN (US) | 2003-09-25 | — | — | WO | disclosed |
| US-20030176352-A1 | Peptides and related compounds having thrombopoietic activity | AMGEN INC. | 2003-09-18 | — | — | US | disclosed |
| US-20030171421-A1 | Methods and compositions for controlling biofilm development | MONTANA STATE UNIVERSITY | 2003-09-11 | — | — | US | disclosed |
| US-6613544-B1 | Secreted polypeptides; tumor necrosis factor receptor; bones; nucleic acids; recombinant vectors; host cells; drugs; bone disorders; therapy; polypeptide used to treat bone diseases such as osteoporosis | AMGEN INC. | 2003-09-02 | — | — | US | disclosed |
| EP-0580692-B1 | AUTOINDUCER | UNIV NOTTINGHAM (GB) | 2003-08-13 | — | — | EP | disclosed |
| WO-2003057134-A2 | SPECIFIC BINDING AGENTS OF HUMAN ANGIOPOIETIN-2 | AMGEN, INC. (US) | 2003-07-17 | — | — | WO | disclosed |
| US-20030105019-A1 | Tumor endothelial marker 5alpha molecules and uses thereof | AMGEN INC. A CORPORATION OF THE STATE OF DELAWARE | 2003-06-05 | — | — | US | disclosed |
| WO-2003031589-A2 | PEPTIDES AND RELATED COMPOUNDS HAVING THROMBOPOIETIC ACTIVITY | AMGEN INC. (US) | 2003-04-17 | — | — | WO | disclosed |
| US-20030050247-A1 | Chemically-modified peptides, compositions, and methods of production and use | HERCULES INCORPORATED | 2003-03-13 | — | — | US | disclosed |
| EP-1278778-A2 | MODIFIED PEPTIDES, COMPRISING AN FC DOMAIN, AS THERAPEUTIC AGENTS | Amgen Inc., (US) | 2003-01-29 | — | — | EP | disclosed |
| US-20030013755-A1 | Autoinducer compounds | MONTANA STATE UNIVERSITY | 2003-01-16 | — | — | US | disclosed |
| EP-0994961-A4 | HOMOSERINE LACTONES BIOFILM REGULATING COMPOUNDS AND THEIR METHODS OF USE | UNIV MONTANA RES DEV INST (US) | 2003-01-15 | — | — | EP | disclosed |
| EP-1274730-A2 | INTEGRIN/ADHESION ANTAGONISTS | Amgen, Inc. (US) | 2003-01-15 | — | — | EP | disclosed |
| EP-1087957-A4 | AUTOINDUCER COMPOUNDS | UNIV MONTANA RES DEV INST (US) | 2003-01-02 | — | — | EP | disclosed |
| EP-1261639-A2 | CHONDROMODULIN-I RELATED PEPTIDE | Amgen Inc. (US) | 2002-12-04 | — | — | EP | disclosed |
| WO-2002092620-A2 | PEPTIDES AND RELATED MOLECULES THAT BIND TO TALL-1 | AMGEN, INC. (US) | 2002-11-21 | — | — | WO | disclosed |
| US-20020168363-A1 | Integrin/adhesion antagonists | AMGEN INC. | 2002-11-14 | — | — | US | disclosed |
| US-6455031-B1 | MIXTURE OF ANALOGS OF BUTYRYL L-HOMO-SERINE LACTONE (BHL) AND BLOCKERS OF N-(3-OXODODECANOLY) L-HOMOSERINE LACTONE (ODDHL) | NATIONAL SCIENCE FOUNDATION | 2002-09-24 | — | — | US | disclosed |
| WO-2001003719-A9 | COMBINATION THERAPY FOR CONDITIONS LEADING TO BONE LOSS | AMGEN INC (US) | 2002-08-08 | — | — | WO | disclosed |
| EP-1196188-A1 | VGF SELECTIVE MONOCLONAL ANTIBODIES AND THEIR USE FOR TREATING VGF-RELATED DISORDERS | Amgen, Inc. (US) | 2002-04-17 | — | — | EP | disclosed |
| EP-1196442-A1 | VGF POLYPEPTIDES AND METHODS OF TREATING VGF-RELATED DISORDERS | Amgen Inc., (US) | 2002-04-17 | — | — | EP | disclosed |
| US-6369027-B1 | FOR THERAPY OF BONE DISEASES CHARACTERIZED BY INCREASED RESORPTION SUCH AS OSTEOPOROSIS | AMGEN INC. | 2002-04-09 | — | — | US | disclosed |
| US-20020009454-A1 | Composition and method for treating inflammatory diseases | AMGEN INC. | 2002-01-24 | — | — | US | disclosed |
| CN-1331701-A | Modified peptides as therapeutic agents | AMGEN INC (US) | 2002-01-16 | — | — | CN | disclosed |
| US-6337347-B1 | ENHANCE GENE EXPRESSION IN A WIDE VARIETY OF MICROORGANISMS, THERAPEUTIC COMPOSITIONS AND THERAPEUTIC METHODS WHEREIN GENE EXPRESSION WITHIN MICROORGANISMS IS REGULATED ARE DISCLOSED. | THE RESEARCH & DEVELOPMENT INSTITUTE, INC. | 2002-01-08 | — | — | US | disclosed |
| WO-2001083525-A2 | MODIFIED PEPTIDES, COMPRISING AN FC DOMAIN, AS THERAPEUTIC AGENTS | AMGEN INC. (US) | 2001-11-08 | — | — | WO | disclosed |
| WO-2001081377-A2 | INTEGRIN/ADHESION ANTAGONISTS | AMGEN, INC. (US) | 2001-11-01 | — | — | WO | disclosed |
| EP-1144454-A2 | MODIFIED PEPTIDES AS THERAPEUTIC AGENTS | Amgen Inc. (US) | 2001-10-17 | — | — | EP | disclosed |
| US-6294170-B1 | PROTEINACEOUS IL-1 INHIBITOR (INTERLEUKIN-1RA) BY EXTENDED DELIVERY MEANS, E.G., CONTROLLED RELEASE POLYMER FORMULATIONS (HYALURONAN), IL-1RA FUSION PROTEINS AND CHEMICAL ATTACHMENT, AND CONTINUOUS PUMP INFUSION, ARTHRITIS, FUSION PROTEIN | AMGEN INC. | 2001-09-25 | — | — | US | disclosed |
| US-6288032-B1 | POLYPEPTIDES FOR OSTEOPOROSIS AND OTHER BONE DISORDER TREATMENT | AMGEN INC. | 2001-09-11 | — | — | US | disclosed |
| US-6284728-B1 | POLYPEPTIDE | AMGEN INC. | 2001-09-04 | — | — | US | disclosed |
| US-6284485-B1 | GENE EXPRESSION, ENGINEERING; OSTEOPOROSIS, BONE DISORDERS; BONE RESORPTION INHIBITION; MUTANTS | AMGEN INC. | 2001-09-04 | — | — | US | disclosed |
| US-6284740-B1 | POLYPEPTIDE | AMGEN INC. | 2001-09-04 | — | — | US | disclosed |
| EP-1124961-A2 | THROMBOPOIETIC COMPOUNDS | Amgen Inc. (US) | 2001-08-22 | — | — | EP | disclosed |
| WO-2001053344-A2 | CHONDROMODULIN-I RELATED PEPTIDE | AMGEN, INC. (US) | 2001-07-26 | — | — | WO | disclosed |
| EP-1087957-A1 | AUTOINDUCER COMPOUNDS | THE RESEARCH AND DEVELOPMENT INSTITUTE, INC (US) | 2001-04-04 | — | — | EP | disclosed |
| WO-2001007074-A1 | VGF SELECTIVE BINDING AGENTS AND METHODS OF TREATING VGF-RELATED DISORDERS | AMGEN, INC. (US) | 2001-02-01 | — | — | WO | disclosed |
| WO-2001007477-A1 | VGF POLYPEPTIDES AND METHODS OF TREATING VGF-RELATED DISORDERS | AMGEN, INC. (US) | 2001-02-01 | — | — | WO | disclosed |
| WO-2001003719-A2 | COMBINATION THERAPY FOR CONDITIONS LEADING TO BONE LOSS | AMGEN INC. (US) | 2001-01-18 | — | — | WO | disclosed |
| US-6143874-A | FOR STIMULATING B-CELL AND/OR T CELL PRODUCTION; ANTIINFLAMMATORY AGENTS; TREATMENT OF ALZHEIMER'S/PARKINSON'S DISEASES, AMYOTROPHIC LATERAL SCLEROSIS, AND VARIOUS DEGENERATIVE DISORDERS THAT AFFECT VISION | AMGEN INC (US) | 2000-11-07 | — | — | US | disclosed |
| WO-2000024770-A9 | DIMERIC THROMBOPOIETIN PEPTIDE MIMETICS BINDING TO MP1 RECEPTOR AND HAVING THROMBOPOIETIC ACTIVITY | AMGEN INC (US) | 2000-10-26 | — | — | WO | disclosed |
| EP-1025122-A1 | FIBROBLAST GROWTH FACTOR WITH HEPATOCYTE PROLIFERATION ACTIVITY | Itoh, Nobuyuki (JP) | 2000-08-09 | — | — | EP | disclosed |
| WO-2000024770-A2 | DIMERIC THROMBOPOIETIN PEPTIDE MIMETICS BINDING TO MP1 RECEPTOR AND HAVING THROMBOPOIETIC ACTIVITY | AMGEN INC. (US) | 2000-05-04 | — | — | WO | disclosed |
| WO-2000024782-A2 | MODIFIED PEPTIDES, COMPRISING AN FC DOMAIN, AS THERAPEUTIC AGENTS | AMGEN INC. (US) | 2000-05-04 | — | — | WO | disclosed |
| EP-0994961-A2 | HOMOSERINE LACTONES BIOFILM REGULATING COMPOUNDS AND THEIR METHODS OF USE | The Research and development Institute, Inc (US) | 2000-04-26 | — | — | EP | disclosed |
| US-6054294-A | NUCLEOTIDE SEQUENCES CODING A NEURONAL POLYPEPTIDE WHICH IS INVOLVED IN THE ACTIVATION OF PROPAGATION OF NEURONS; FOR THE TREATMENT OF PARKINSON'S DISEASE AND AMYOTROPHIC LATERAL SCLEROSIS | AMGEN INC. (US) | 2000-04-25 | — | — | US | disclosed |
| EP-0977859-A1 | THE NEUROTROPHIC FACTOR NNT-1 | AMGEN INC. (US) | 2000-02-09 | — | — | EP | disclosed |
| US-6015938-A | TRANSGENIC NON-HUMAN MAMMAL HAVING NUCLEIC ACID CODING FOR A MEMBER OF THE TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY INTEGRATED INTO ITS GENOME; WITH INCREASED BONE DENSITY | AMGEN INC. (US) | 2000-01-18 | — | — | US | disclosed |
| WO-1999065889-A1 | AUTOINDUCER COMPOUNDS | THE RESEARCH AND DEVELOPMENT INSTITUTE (US) | 1999-12-23 | — | — | WO | disclosed |
| US-5998170-A | Polynucleotides encoding hepatocyte-specific members of the FGF family | AMGEN INC. (US) | 1999-12-07 | — | — | US | disclosed |
| WO-1999018128-A1 | FIBROBLAST GROWTH FACTOR WITH HEPATOCYTE PROLIFERATION ACTIVITY | AMGEN INC. (US) | 1999-04-15 | — | — | WO | disclosed |
| WO-1998058075-A2 | HOMOSERINE LACTONES BIOFILM REGULATING COMPOUNDS AND THEIR METHODS OF USE | THE RESEARCH AND DEVELOPMENT INSTITUTE, INC. (US) | 1998-12-23 | — | — | WO | disclosed |
| WO-1998057618-A1 | METHODS AND COMPOSITIONS FOR CONTROLLING BIOFILM DEVELOPMENT | THE RESEARCH AND DEVELOPMENT INSTITUTE, INC. (US) | 1998-12-23 | — | — | WO | disclosed |
| EP-0870023-A1 | OSTEOPROTEGERIN | AMGEN INC. (US) | 1998-10-14 | — | — | EP | disclosed |
| WO-1998033922-A1 | THE NEUROTROPHIC FACTOR NNT-1 | AMGEN INC. (US) | 1998-08-06 | — | — | WO | disclosed |
| WO-1998024907-A1 | NOVEL PROTEIN WITH CHEMOKINE ACTIVITY | AMGEN INC. (US) | 1998-06-11 | — | — | WO | disclosed |
| US-5741772-A | POLYPEPTIDE | AMGEN INC. (US) | 1998-04-21 | — | — | US | disclosed |
| EP-0784093-A1 | Osteoprotegerin | AMGEN INC. (US) | 1997-07-16 | — | — | EP | disclosed |
| WO-1997023614-A1 | OSTEOPROTEGERIN | AMGEN INC. (US) | 1997-07-03 | — | — | WO | disclosed |
| US-5593827-A | N-(BETA-KETOCAPROYL) HOMOSERINE LACTONE OR ANALOGUE | THE UNIVERSITY OF NOTTINGHAM (GB) | 1997-01-14 | — | — | US | disclosed |
| EP-0580692-A1 | AUTOINDUCER | THE UNIVERSITY OF NOTTINGHAM (GB) | 1994-02-02 | — | — | EP | disclosed |
| WO-1992018614-A1 | AUTOINDUCER | THE UNIVERSITY OF NOTTINGHAM (GB) | 1992-10-29 | — | — | WO | disclosed |
| WO-1992018614-A1 | AUTOINDUCER | THE UNIVERSITY OF NOTTINGHAM (GB) | 1992-10-29 | — | — | WO | disclosed |